Compare Ascendis Pharma A/S (ASND) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Msci Inc — how do they compare? Ascendis Pharma A/S trades at $255 (market cap $16.67B), while Msci Inc trades at $565 (market cap $40.84B). The key difference: Msci Inc is far larger — about 2.4× Ascendis Pharma A/S's market cap, and Msci Inc pays a 1.46% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MSCI | |
|---|---|---|
Market Cap | $16.67B | $40.84B |
Sector | Health | Financials |
52-Week High | $277.18 | $643.83 |
52-Week Low | $189.74 | $511.84 |
Enterprise Value | $17.04B | $47.00B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
MSCI trades at $563.01, down slightly (-0.01%) with a bearish technical signal. The company maintains strong fundamentals with $3.13B revenue, 40.73% net margin, and consistent earnings beats in three of the last four quarters. Recent acquisitions and strategic partnerships enhance its private markets platform. Analyst consensus remains strongly bullish with a $728.14 price target, representing 29% upside potential from current levels.
The outlook remains positive given MSCI's recurring revenue model, high client retention, and secular growth in private markets. Key risks include execution of recent acquisitions and market sensitivity to index performance. With strong profitability and Wall Street support, the stock presents a compelling long-term opportunity despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
